Dataset Information


Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

ABSTRACT: This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab plus cyclophosphamide, vincristine, and prednisone [R-CVP]) for treatment-naive patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma. Investigators preassigned the standard treatment regimen they considered most appropriate for each patient; patients were randomized to receive BR (n = 224) or standard therapy (R-CHOP/R-CVP, n = 223) for 6 cycles; 2 additional cycles were permitted at investigator discretion. Response was assessed by a blinded independent review committee. BR was noninferior to R-CHOP/R-CVP, as assessed by the primary end point of complete response rate (31% vs 25%, respectively; P = .0225 for NI [0.88 margin]). The overall response rates for BR and R-CHOP/R-CVP were 97% and 91%, respectively (P = .0102). Incidences of vomiting and drug-hypersensitivity reactions were significantly higher in patients treated with BR (P < .05), and incidences of peripheral neuropathy/paresthesia and alopecia were significantly higher in patients treated with standard-therapy regimens (P < .05). These data indicate BR is noninferior to standard therapy with regard to clinical response with an acceptable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT00877006.


PROVIDER: S-EPMC4260975 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6494265 | BioStudies
2020-01-01 | S-EPMC6960034 | BioStudies
2019-01-01 | S-EPMC6486816 | BioStudies
2011-01-01 | S-EPMC3269215 | BioStudies
2020-01-01 | S-EPMC7154735 | BioStudies
2015-01-01 | S-EPMC4616024 | BioStudies
2019-01-01 | S-EPMC6555660 | BioStudies
2009-01-01 | S-EPMC2783818 | BioStudies
2020-01-01 | S-EPMC7422137 | BioStudies
2015-01-01 | S-EPMC4380725 | BioStudies